Breast Cancer Index (BCI) is a molecular, gene expression-based test uniquely positioned to identify patients best suited for extended endocrine treatment. It is the only validated, commercially available test that provides prognostic risk of late recurrence (5-10 years post-diagnosis), as well as prediction of extended endocrine therapy benefit. The breakthrough test helps oncologists and patients navigate the difficult trade-off between wanting to take steps to prevent recurrence of their disease and facing significant side effects and safety challenges related to extended endocrine therapy. Breast Cancer Index (BCI) was granted Medicare coverage in October 2014.
For more information, visit: http://www.breastcancerindex.com
http://www.answersbeyond5.com
http://www.twitter.com/answersbyond5